Limitations
inflammation, tumor necrosis
INFLAMMATION, TUMOR NECROSIS
First, the intervention was relatively brief and future studies will need to examine whether individual treatment differences based on inflammatory profiles persisted over follow‐up. Second, our assessment of inflammation was limited to hsCRP, whereas future studies should collect a richer array of inflammatory markers. However, we note that when inflammatory data from a subset of participants who also had tumor necrosis factor‐alpha levels collected were integrated with hsCRP, our observation that baseline inflammation moderated the effects of treatment persisted (